December 9, 2022 —  Imbria Pharmaceuticals, Inc., a clinical stage, cardiometabolic company developing novel therapies designed to enhance cellular energetics, today announced that Martin Maron, M.D., director of HCM Center at Lahey Medical Center, at the 19th Annual Global Cardio Vascular Clinical Trialists (CVCT) Forum in Washington D.C., highlighted the importance of cardiac energetic deficits in non-obstructive hypertrophic cardiomyopathy (nHCM) and how the cardiac mitotrope, ninerafaxstat, may be life changing for patients living with nHCM.

December 8, 2022 — Heart disease is the number one killer in the U.S., and high-fidelity monitoring is the beginning of new prospects for patients with congestive heart failure (CHF).

December 8, 2022 — Esperion announced that the landmark Cholesterol Lowering via Bempedoic acid, an ACL-Inhibiting Regimen (CLEAR) Outcomes trial met its primary endpoint, demonstrating statistically significant risk reduction in MACE-4 in patients treated with 180 mg/day NEXLETOL compared to placebo.

December 8, 2022 — The Society for Cardiovascular Angiography & Interventions (SCAI), a leading nonprofit medical society representing interventional cardiology (IC) is excited to formally announce that the subspecialty will join the NRMP’s Medical Specialties Matching Program (“the Match”) in 2025.

December 8, 2022 — Butterfly Network, Inc., a digital health company transforming care with handheld, whole-body ultrasound, announced that the Company and Todd Fruchterman, M.D., Ph.D. have mutually agreed that Dr. Fruchterman will leave his position as President and Chief Executive Officer and as a member of the Board of Directors. Dr.

December 7, 2022 —  While heart disease is a leading cause of death in the United States, most people can be treated with early detection and timely interventions. That’s why Zheng Yan and a team of researchers at the University of Missouri are using a $2.6 million grant from the National Institutes of Health (NIH) to help create a breathable material — with antibacterial and antiviral properties — to support the team’s ongoing development of a multifunctional, wearable heart monitor. 

December 7, 2022 —  Compared with team-based care alone, the addition of a computerized clinical decision support system (CDSS) significantly reduced cardiovascular risk factors in patients with diabetes. These findings may have important public health and clinical significance in low- and middle-income countries where there is a lack of diabetes specialists to manage patients. The findings are published in Annals of Internal Medicine. 

December 7, 2022 —   BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today anno

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now